Copyright
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 21, 2018; 24(23): 2501-2507
Published online Jun 21, 2018. doi: 10.3748/wjg.v24.i23.2501
Published online Jun 21, 2018. doi: 10.3748/wjg.v24.i23.2501
Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus
Lin-Zhong Zhu, Department of Interventional Therapy, Beijing Cancer Hospital, Beijing 100142, China
Song Xu, Department of Radiology, Yunnan Second People’s Hospital, Kunming 650021, Yunnan Province, China
Hai-Long Qian, Interventional Therapy, Baotou Cancer Hospital, Baotou 014030, Inner Mongolia, China
Author contributions: Zhu LZ and Qian HL designed and performed this study; Zhu LZ analyzed the data; Xu S wrote the paper; Zhu LZ revised the manuscript for final submission.
Supported by the National Key R and D Program of China , No. 2016YFC0106604 ; and the National Natural Science Foundation of China , No. 81502591 .
Institutional review board statement: The study was reviewed and approved by the Peking University Cancer Hospital’s Institutional Review Board.
Institutional animal care and use committee statement: The pharmacokinetics study was reviewed and approved by the Department of Laboratory Animal Science, Peking University Health Science Center.
Conflict-of-interest statement: The authors declare, to the best of our knowledge, no conflict of interest exists.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hai-Long Qian, MD, Doctor, Department of Interventional Therapy, Baotou Cancer Hospital, 18 Tuanjie Street, Qingshan District, Baotou 014030, Inner Mongolia, China. hailongqian@163.com
Telephone: +86-472-5156644
Received: February 7, 2018
Peer-review started: February 7, 2018
First decision: February 24, 2018
Revised: March 9, 2018
Accepted: March 25, 2018
Article in press: March 25, 2018
Published online: June 21, 2018
Processing time: 128 Days and 1.3 Hours
Peer-review started: February 7, 2018
First decision: February 24, 2018
Revised: March 9, 2018
Accepted: March 25, 2018
Article in press: March 25, 2018
Published online: June 21, 2018
Processing time: 128 Days and 1.3 Hours
Core Tip
Core tip: We analyzed the pharmacokinetic and pharmacodynamic characteristics of continuous hepatic arterial infusion of oxaliplatin and raltitrexed to aid interventional radiologist in determining a more accurate infusion protocol. The clinical protocol based on the pharmacokinetics study in a swine model and the pharmacodynamics study in tumor cell lines was shown to be effective and safe in hepatocellular carcinoma with main portal vein tumor thrombus.